Becatecarin Helsinn Healthcare

IDrugs

Volumn 8, Issue 10, 2005, Pages 838-847

  Rewcastle, Gordon W ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

1,11 DICHLORO 6 (2 DIETHYLAMINOETHYL) 12,13 DIHYDRO 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 (4 O METHYLGLUCOSIDE); ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BECATECARIN; BMS 181176; BMY 27557; BMY 27557 14; CISPLATIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; INTERCALATING AGENT; NSC D640199; ORPHAN DRUG; REBECCAMYCIN; UNCLASSIFIED DRUG; XL 119;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ARTICLE; BILE DUCT CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG INFORMATION; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HUMAN; INOPERABLE CANCER; NAUSEA; NEUTROPENIA; NONHUMAN; PHLEBITIS; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; TREATMENT INDICATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBAZOLES; CLINICAL TRIALS; DNA TOPOISOMERASES, TYPE II; FLUOROURACIL; GLUCOSIDES; HUMANS; INDOLES; LEUCOVORIN; RANDOMIZED CONTROLLED TRIALS; SURVIVAL;

EID: 26944481508     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. 842 Promising new agents unoder development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute. Christian MC, Pluda JM, Ho PTC, Arbuck SG, Murgo AJ, Sausville EA SEMIN ONCOL 1997 24 2 219-240
2. 808 Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle. Moreau P, Anizon F, Sancelme M, Prudhomme M, Bailly C, Carrasco C, Ollier M, Severe D. Riou JF, Fabbro D, Meyer T, Aubertin AM J MED CHEM 1998 41 10 1631-1640
3. 079 Cytochrome P-450 metabolism of the rebeccamycin analog NSC655649. Rizzo J, Renouf J, Eckhardt SG, Waltman S, Rowinsky E, Kuhn J ANN ONCOL 1998 9 2 Abs 231
4. 786 A phase I and phermacokinetic (PK) study of the rebeccamycin analog NSC 655649 In patients with advanced cancer. Eckhardt SG, Kuhn J. Rizzo J, Sharma S, Campbell E, Ivey P, Weiss G, Hammond L, Kraynak M, Von Hoff DD, Rowinsky EK ANN ONCOL 1998 92 Abs 250
5. 152 hi vitro antitumor activity of rebeccamycin analog (NSC# 655649) against Pediatric solid tumors. Weitman S, Moore R, Barrera H, Cheung NK, Ibicka E, Von Hoff DD J PEDIATR HEMATOL/ONCOL 1998 20 2 136-139
6. 208 Water soluble derivatives of rebeccamycin. Kansko T, Wong H, Utzig J, Schuring J, Doyle TW J ANTIBIOT 1990 43 1 125-127 ]]The first publication on the development of becatecarin including chemical synthesis and early in vivo investigations.
7. 222 Phase I clinical and pharmacokinetic study of a rebeccamycin analog (NSC 655649). Cleary JF, Berlin JD, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Morgan K, Mamocha R, Wilding G PROC AM SOC CLIN ONCOL 1997 16 217a Abs 760
8. 034 A phase I clinical and pharmacokinetic study of rebeccamycin analog (NSC-655649) given daily for five consecutive days, Villelona Calero M, Eckhardt SG, Hammond L, Campbell E, Smith L, Hidalgo M, Britten C, Beijnen J, Guzman C, Jimeno J, Von Hoff D et al PROC AM SOC CLIN ONCOL 1999 18 May 15-18 Abs 694
9. 109 A trial of rebeccamycin analog NSC-655649 in children with solid tumors: A Pediatric Oncology Group phase I cooperative agreement study. Langevin A, Weitman S, Juhn S, Bornstein M PROC AM SOC CLIN ONCOL 1999 18 May 15-18 Abs 764
10. 407089 Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days. Dowlati A, Hoppel CL, Ingalls ST, Maika S, Li X, Sedransk N, Spiro T, Gerson SL, Ivy P, Remick SC J CLIN ONCOL 2001 19 8 2309-2318 ]]Phase I clinical trial of becatecarin showing the drug to have encounraging antitumor activity.
11. 410637 Rebeccamycin analog (BMY- 27557-44) In renal cell cancer (RCC): Preliminary results of a phase II trial. Ibrahim D, Hussain M, LoRusso P, Flaherty L PROC AM SOC CLIN ONCOL 2001 20 Pt2 Abs 2373
12. 416062 Bristol_Myers Squibb and Exelixis enter pioneering cancerfighting alliance. Bristol Myers Squibb Co PRESS RELEASE 2001 July 18
13. 416610 Exelixis Inc. COMPANY COMMUNICATION 2001 July 24
14. 436252 Exelixis Inc. HAMBRECHT & QUIST 2002 January 07-10 144
15. 451864 Phase I and pharmacokinetic (PK) trial of sequences of the rebeccamycin analog, NSC 655649, and cisplatin (CDDP). Hammond LA, Kuhn J, Ochoa L, Hao D, Forouzesh B, Forero L, Mays T, Patnaik A, Tolcher AW, Berg KE, Rowinsky EK PROC AM SOC CLIN ONCOL 2002 21 1 Abs 380
16. 471762 Pediatric studies and hematological malignancies. McKinnon C IDRUGS 1999 2 7 636-638
17. 492220 Multicenter phase II and pharmaconetic study of rebeccamycin analogue (RA) In advanced billary cancers. Dowlati A, Posey J, Ramanathan RK, Rath L, Sellers S, Schmotzer A, Ingalls S, Hoppel C, Ivy P, Remick C PROC AM SOC CLIN ONCOL 2003 22 Aba 1070 ]]Phase II clinical trial results suggesft the enhanced clinical benefit of becatecarin in advanced billary tumors.
18. 493633 Randomized phase II trial of 2 different administration schedules of rebeccamycin analogue (RA) as 2nd line therapy In patients (pts) with advanced non-small cell lung cancer (NSCLC). Cortas T, Ness A, Chapman R, Remick S, Levitan N, Schmidt C, Patrick L, Xu N, Ivy P, Dowlati A PROC AM SOC CLIN ONCOL 2003 22 Abs 2686
19. 507598 Blopartnering - Exelixis Inc. ANNU BIOPARTNERING EUROPE MEET 2003 11 October 12-14
20. 517412 Exelixis filles IND application for XL119. Exelixis Inc PRESS RELEASE 2003 December 17
21. 527248 Exelexis granted orphan drug designation for anticancer agent XI119. Exelixis Inc PRESS RELEASE 2004 March 15
22. 529215 Phase I trial of rebeccamycin analog (NSC #656649) in children with refractory solid tumors: A Pediatric Oncology Group study. Langevin A-M, Waltman SD, Kuhn JG, Weintraub ST, Baruchel S, Furman W, Bernstein M, Blaney S, Vietti T J PEDIATR HEMATOL/ONCOL 2003 25 7 526-533
23. 529216 A phase II study of rebeccamycin analog NSC 655649 In Patients with metastatic colorectal cancer. Goel S, Wadler S, Hoffman A, Volterra F, Baker C, Nazario, E, Ivy P, Silverman A, Mani S INVESTIG NEW DRUGS 2003 21 1 103-107 ]]Phase II clinical trial results showing becatecarin has no antitumor activity against metastatic colorectal cancer.
24. 529217 A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer. Hussain M, Vaishampayan U, Heitbrun LK, Jain V, LoRusso PM, Ivy P, Flaherty L INVESTIG NEW DRUGS 2003 21 4 465-471 ]]Phase II clinical trial results reporting that becatecarin has only modest antitumor activity against metastatic renal cell cancer.
25. 529218 Phase I clinical and pharmacokinetic study. of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats. Merchant J, Tutsch K, Dresen A, Arzoomanian R, Alberti D, Feierabend C, Binger K, Mamoccha R, Thomas J, Cleary J, Wilding G CLIN CANCER RES 2002 8 7 2193-2201
26. 529219 Discovery of antitumor Indolocarbazolesn Rebeccamycin, NSC 655649, and fluoroindolocarbazoles. Long BH, Rose WC, Vyas DM, Matson JA, Forenza S CURR MED CHEM ANTI-CANC AGENTS 2002 2 2 255-266 ]]Review article by SMS authors that describes the discovery of rabeccamycin and analogs including becatecarin.
27. 529220 Phase I and pharmacokinetic Study of NSC 655649 a rebeccamycin analog with topoisomerase inhibitory properties. Tolcher AW, Eckhardt SG, Kuhn J, Hammond L, Weiss G, Rizzo J, Aylesworth C, Hidalgo M, Patnaik A, Schwartz G, Felton S, Campbell E, Flowinsky EK J CLIN ONCOL 2001 19 11 2937-2947 ]]Phase I clinical trial results showing encouraging antitumor activity of becatecarin in heavily prefreated solid tumor patients.
28. 529221 Production, Isolation and structure determination of novel fluoroindolocarbazoles from Saccharothrix aerocolonigenes ATCC 39243. Lam KS, Schroeder DR, Veitch JM, Colson KL, Matson JA, Row WC, Doyle TW, Forenza S J ANTIBIOT 2001 54 1 1-9
29. 531830 Characterization of the human cytochrome P450 (CYP450) isozymes Involved In the metabolism of rebeccamycin analog (NSC 655649). Sevak R, Delacruz P, Kosiba I, Kuhn JG PROC ANNU MEET AM ASSOC CANCER RES 2004 45 Abs 2116
30. 542952 Rebeccamycin analog for refractory breast cancer: A randomized phase II trial. Burstein HJ PROC AM SOC CLIN ONCOL 2004 23 Abs 547
31. 545866 Exellixis; Initiales phase 3 clinical trial of XL119 In bite duct cancer. Exelixis Inc PRESS RELEASE 2004 June 23
32. 575029 plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655648) in nonhurnan primates. Berg S, Aleksic A, McGuffey L, Dauser R, Nuchtern J, Bernacky B, Blaney SM CANCER CHEMOTHER PHARMACOL 2004 54 127-130
33. 606977 Exelixis and Helsinn sign agreement for XL119 (becatecarin). Exelixis Inc PRESS RELEASE 2005 June 13
34. 609122 Fluorescence polarization studies of the binding of SM 181176 to DNA. Krishnan BS, Moore ME, Lavoie CP, Long BH, Dalterio RA, Wong HS, Rosenberg IE J BIOMOL STRUCT DYNAM 1994 12 3 625-636
35. 611954 Clinical trial information: Becatecarin. INTERNET SITE 2005 June 30 http://www.clinicaltrials.gov
36. 613960 Production and biological activity of rebeccamycin, a novel antitumor agent. Bush JA, Long BH, Catino JJ, Bradner WT, Tomita K J ANTIBIOT 1987 40 5 668-678